COLON ADENOCARCINOMA
Clinical trials for COLON ADENOCARCINOMA explained in plain language.
Never miss a new study
Get alerted when new COLON ADENOCARCINOMA trials appear
Sign up with your email to follow new studies for COLON ADENOCARCINOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New drug cocktail aims to stop BRAF colon cancer in its tracks
Disease control OngoingThis study tests whether adding two targeted drugs (encorafenib and cetuximab) after standard surgery and chemotherapy can lower the chance of cancer coming back in people with a specific genetic type of stage II/III colon cancer (BRAF V600E). Participants either receive the drug…
Matched conditions: COLON ADENOCARCINOMA
Phase: PHASE2, PHASE3 • Sponsor: Alliance for Clinical Trials in Oncology • Aim: Disease control
Last updated May 26, 2026 09:43 UTC
-
New hope for colon cancer: study tests adding avastin to standard chemo
Disease control OngoingThis study looked at over 2,400 people with stage II colon cancer who had a high chance of the cancer coming back after surgery. It compared standard chemotherapy (FOLFOX) to the same chemo plus a targeted drug called bevacizumab (Avastin). The goal was to see if adding Avastin h…
Matched conditions: COLON ADENOCARCINOMA
Phase: PHASE3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 26, 2026 09:31 UTC
-
Immunotherapy combo shows promise in High-Risk colon cancer trial
Disease control OngoingThis study tests whether adding the immunotherapy drug atezolizumab to standard chemotherapy helps prevent cancer from returning in people with stage III colon cancer that has a specific DNA repair problem (dMMR). About 712 participants received either chemotherapy alone or chemo…
Matched conditions: COLON ADENOCARCINOMA
Phase: PHASE3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 26, 2026 09:28 UTC
-
New combo therapy aims to stall hard-to-treat colon cancer
Disease control OngoingThis study tests a two-drug combination (cabozantinib and nivolumab) in people with advanced colorectal cancer that is microsatellite stable (MSS) and has stopped responding to standard treatments. The goal is to see if the combination can control the cancer for at least 16 weeks…
Matched conditions: COLON ADENOCARCINOMA
Phase: PHASE2 • Sponsor: University of Colorado, Denver • Aim: Disease control
Last updated May 26, 2026 09:26 UTC
-
Scientists hunt for genetic clues to rising colorectal cancer in young people
Knowledge-focused OngoingThis study looks at genetic factors that may increase the risk of developing colorectal cancer at a young age (18-50). Researchers will compare medical records, lifestyle information, and genetic data from 818 patients and their family members. The goal is to find genetic markers…
Matched conditions: COLON ADENOCARCINOMA
Sponsor: M.D. Anderson Cancer Center • Aim: Knowledge-focused
Last updated May 26, 2026 09:44 UTC